19:15 , Jul 19, 2019 |  BC Extra  |  Financial News

July 19 Financial Quick Takes: Amarin raises cash ahead of Vascepa PDUFA date, plus Atara, Sunstone and Forendo

Ahead of Vascepa push, Amarin adds $400M to coffers  With the Sept. 28 PDUFA date looming for a potential expansion of the label for Vascepa icosapent to include reduced cardiovascular risk, Amarin Corp. plc (NASDAQ:AMRN)...
22:41 , Jun 25, 2019 |  BC Extra  |  Financial News

June 25 Financial Quick Takes: Tasly unit planning Hong Kong IPO; plus Vesalius, Mirati and more

Tasly Biopharma looks to list in Hong Kong  Tasly Biopharmaceutical Co. Ltd. (Shanghai, China) proposed to list on the Hong Kong exchange. The company is a subsidiary of Tasly Pharmaceutical (Shanghai:600535), which holds 87.75% of...
18:43 , May 22, 2019 |  BC Extra  |  Company News

AlloVir, first to test ElevateBio's model, raises $120M ahead of Phase III

The first disclosed company that will test newly launched ElevateBio's cell and gene therapy model is antiviral treatment developer AlloVir, which revealed the companies' relationship along with a $120 million series B round on Wednesday....
23:30 , May 13, 2019 |  BioCentury  |  Finance

How ElevateBio plans to create portfolio of cell, gene therapy newcos with $150M MPM, F2-led round

With $150 million in series A funding and an executive team led by Alexion and bluebird veterans, ElevateBio emerged from stealth on Monday with plans to accelerate cell and gene therapy discovery and development by...
22:23 , May 10, 2019 |  BC Extra  |  Financial News

May 10 Financial Quick Takes: Intercept raises over $400M; plus 28-7, LunaPBC

Intercept raises $410.4M via sales of stock, notes  Liver disease company Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) raised $200.4 million through the sale of 2.4 million shares at $83.50 in a follow-on, another $200 million through the...
10:30 , Apr 1, 2019 |  BC Extra  |  Financial News

SpringWorks raises $125M series B round

A year and a half after raising its initial round of funding to develop programs spun out of Pfizer, SpringWorks has raised $125 million in a series B round. The company now has funding to...
23:20 , Mar 15, 2019 |  BioCentury  |  Emerging Company Profile

Neurogene: Genes over ERT for monogenic CNS diseases

Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in which enzyme replacement is not feasible or hasn't been explored. Aspartylglucosaminuria (AGU) is a lysosomal storage disorder caused by autosomal recessive AGA mutations...
20:00 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Hookipa raises $37.4M series D

Hookipa Pharma Inc. (New York, N.Y.) raised $37.4 million (€33 million) on Feb. 26 in a series D round led by Redmile Group. The company is developing a pipeline of vaccines based on its VaxWave...
18:28 , Feb 26, 2019 |  BC Extra  |  Financial News

Hookipa seeking clinical progress with $37.4M series D round

Hookipa Pharma Inc. (New York, N.Y.) raised $37.4 million (€33 million) in a series D round of funding led by Redmile Group. The company is developing a pipeline of vaccines based on its VaxWave and...
18:41 , Feb 15, 2019 |  BC Week In Review  |  Financial News

Neurogene raises $68.5M series A for neurological disease gene therapies

Neurogene Inc. (New York, N.Y.) raised $68.5 million in a series A round to fund development of its adeno-associated viral (AAV)-based gene therapies to treat rare neurological diseases. Samsara BioCapital, EcoR1 Capital, Cormorant Asset Management,...